Nivolumab Has Antitumor Activity in dMMR/MSI-H Colorectal Cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2017-141
Abstract: Nivolumab is safe and achieves durable responses in metastatic dMMR/MSI-H colorectal cancer. read more here.
Keywords: cancer; colorectal cancer; msi colorectal; dmmr msi ... See more keywords
Case report: A combined immunotherapy strategy as a promising therapy for MSI-H colorectal carcinomas with multiple HPD risk factors
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2023.1051034
Abstract: Approximately 5% of advanced colorectal carcinomas (CRCs) and 12–15% of early CRCs are microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. Nowadays, PD-L1 inhibitors or combined CTLA4 inhibitors are the major strategies for advanced or… read more here.
Keywords: colorectal carcinomas; combined immunotherapy; risk factors; case ... See more keywords